Objective: To determine the relationship of Vitamin D levels with anthropometric measurements at time of peak bone mass.
Pelvic Pain Intensity Scales Are Comparable

Measurement of Acute Pelvic Pain Intensity in Gynecology. A Comparison of Five Methods.
Fauconnier A, Dallongeville E, et al: Obstet Gynecol; Clinicians generally develop their own way of determining the intensity of pain in their patients. This is usually a combination of direct observation of the patient, specific questions, and physical findings.
Objective: To study and compare methods of pelvic pain intensity measurement in gynecologic emergency units. Design: Prospective cohort study. Participants: 177 consecutive females presenting in a gynecologic emergency unit. Methods: Patients aged 13 years who presented with or without acute pelvic pain in a gynecologic emergency unit were subjected to 5 different scales of measuring pelvic pain intensity. Patients were excluded who had pain from other locations, pregnancy of 20 weeks' gestation, and pathology that may be causing severe chronic pelvic pain. Three self-reported scales were used for all patients, including a visual analog scale, a numerical rating scale, and a 5-level verbal rating scale. In addition to these 3 self-reported scales, the investigators used a behavioral scale index that included vocal complaints, facial expression, movement, and posturing. The separate behavioral index that was specifically developed for this study included pain-related behavior categorized by 8 different criteria. The relevant diagnosis was considered to be the diagnosis determined at the time of patient discharge. The predictive value of the various pain scoring methods was determined according to several factors that are thought to be associated with pain intensity, including the pathology of the final diagnosis, the anatomic location of the disease, the various autonomic pathways that could be involved, and the mechanism of pain. The investigators also considered the prognosis of the disease and other demographic characteristics in order to make the comparisons between the 5 different methods.
Results:
Among the 177 patients who were evaluated, missing data rates were greater for the behavioral scales as compared to the self-reported scales. The pain scores were lower for the behavioral scales than those that were self-reported. Regardless of what method of pain measurement used, the variation of pain intensity according to the pain physiology or the pain location was similar. All 5 methods were sensitive to the physiology of the pain, the location of the pain, the severity of illness, and the observation that pain was the main complaint. The patient's age, occupational categories, parity, or geographic origins did not affect any of the methods of pain intensity measurement.
Conclusions:
Adequate measurement of pelvic pain intensity can be accomplished by use of all 5 methods employed in this study. The self-reported scales are easier to use as compared to the behavioral indices.
Reviewer's Comments:
The intensity of pain is a hard thing to quantitate. Pain scales can be subjective, complex, and difficult to interpret. print tag: () Refer to original journal article.
Coenzyme A Reductase Inhibitors (Statins) Are Good Adjunctive Tx for PCOS
The Effect of Atorvastatin in Patient With Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled
Study.
Sathyapalan T, Kilpatrick ES, et al: J Clin Endocrinol Metab; [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] Statins may improve PCOS and reduce future CVD morbidity.
Objective:
To study the effect of atorvastatin on inflammatory markers, insulin resistance, and hyperandrogenemia in patients with polycystic ovary syndrome (PCOS). Design/Methods: 40 patients fulfilling the criteria for PCOS with hyperandrogenemia and increased insulin resistance were randomized in this double-blind placebo-controlled study to receive either 20 mg of atorvastatin or placebo daily for 12 weeks. Appropriate biochemical markers were obtained at baseline and at the conclusion of the study.
Results: Following 12 weeks of atorvastatin therapy, there was a significant reduction in total cholesterol, LDL-C, triglycerides, high-sensitivity C-reactive protein, and free testosterone compared with the placebo group. In addition, insulin resistance was significantly lower in the statin-treated group, which correlated with the reduction in triglycerides and free androgen index.
Conclusions:
A short-term course of atorvastatin was effective in reducing biochemical markers of inflammation and hyperandrogenemia while improving lipid panels in women with PCOS.
Reviewer's Comments: This was a nice, clean 12-week study that showed the beneficial effects of atorvastatin (Lipitor) on not only lipid panels, but also biochemical markers of inflammation, insulin resistance, and free testosterone in women with PCOS. This article provides further support that statins may have a role in the management of PCOS, particularly in ameliorating hyperandrogenemia and dyslipidemia, and perhaps protecting against future cardiovascular morbidity and mortality. 
Lactation Decreases Risk of Myocardial Infarction
Duration of Lactation and Incidence of Myocardial Infarction in Middle to Late Adulthood.
Stuebe AM, Michels KB, et al: Am J Obstet Gynecol; The changes in glucose and lipid metabolism associated with lactation may produce long lasting effects with subsequent decrease in cardiovascular risks.
Objective: To study the relationship between lactation and myocardial infarction. Design: Prospective cohort study. Participants: 121,700 women involved in the Nurses' Health Study. Methods: The Nurses' Health Study has followed patients at 2-year intervals since 1976 by completing questionnaires regarding health-related topics and medical diagnoses. Lactation history was assessed in 1986, at which time the youngest women in the cohort were age 40 years. There were only 75 births after 1986. These investigators assessed the incidence of non-fatal myocardial infarction and mortality because of coronary heart disease over the years 1986 to 2002, and then calculated the relative risk of myocardial infarction relative to the lactation history. The investigators stratified lactation history into 6 groups: none; >0 to 3 months; >3 to 6 months; >6 to 11 months; >11 to 23 months; and >23 months.
Results: Lactation history was reported by 89,326 parous women. Sixty-three percent of these women had not breast fed. There were 2540 incident cases of myocardial infarction or death because of coronary heart disease among the cohort. For those women reporting a >23-month history of lifetime lactation, the hazard ratio for coronary heart disease was 0.63 with a 95% confidence interval of 0.51 to 0.77 as compared with women who had never breastfed. With the addition of coronary and lifestyle risk factors, the hazard ratio was 0.77 for women with >23 months of lifetime lactation.
Conclusions:
There is a significant inverse relationship for myocardial risks associated with >2 years of lifetime lactation.
Reviewer's Comments: Based on this study, there is a possibility that lactation may be a modifiable risk factor that can reduce cardiac risk in women. 
Chlamydia trachomatis Infection Major Contributor to Tubal Infertility
Chlamydia trachomatis Infection in Women With Secondary Infertility. Malik A, Jain S, et al: Fertil Steril; [91] [92] [93] [94] [95] Past chlamydial infection is strongly associated with secondary infertility, and current infection is commonly present in women with secondary infertility.
Objective: To prospectively assess the role of Chlamydia trachomatis infection in secondary infertility. Design/Methods: This was a prospective study including 40 women with secondary infertility and 30 healthy term pregnant women of similar age. Past Chlamydia trachomatis infection was determined by ELISA assay of Chlamydia IgG antibodies. Present infection was detected by positive endocervical swabs and ELISA assay to detect Chlamydia antigen. In all women with secondary infertility, hysterosalpingography was performed to assess tubal patency.
Results: IgG antibodies to chlamydia were present in 55.0% of women with secondary infertility compared with 5.5% of the controls. Tubal occlusion occurred in two thirds of cases positive for chlamydial antibody, and one third of patients with a past history of chlamydial infection as judged by antibody testing were found to have an active present chlamydial infection.
Conclusions:
Past chlamydial infection is strongly associated with secondary infertility, and current infection is commonly present in these women with secondary infertility as well.
Reviewer's Comments: This article points out the association of past Chlamydia trachomatis infection with tubal disease and infertility. It also emphasizes the recurrent nature of chlamydial infections and the difficulty of detecting chlamydia early, prior to its ability to induce tubal dysfunction and occlusion. It's a bad, frequently silent infection that is a significant contributor to reproductive agony. The duration of treatment for NAS is directly related to the amount of methadone used by the mother during pregnancy.
Objective: To determine if there is a relationship between the dose of maternal methadone used and subsequent duration of neonatal abstinence syndrome (NAS).
Design/Methods:
This was a retrospective cohort study done over a 5.5-year period. Pregnant patients using methadone therapy were evaluated. The amount of methadone used was quantitated for each patient as well as the indication for methadone usage. Patients were divided according to the amount of methadone used. There were 3 groups evaluated: 70 mg a day, 71 to 139 mg a day, and 140 mg a day. Each infant was subsequently evaluated for NAS using a scoring system. Utilizing the NAS scoring system, infants were subsequently treated medically. Medical therapy for the infants included phenobarbital and/or methadone. Infants that were medically treated were subsequently weaned from the specific medication and then discharged either 1 or 2 days after discontinuing the medication. The time that the infant underwent treatment for withdrawal from maternal methadone was calculated for each infant.
Results: There were 66 mother-infant pairs included. Demographics of the 3 groups were no different in regard to age, hepatitis C status, ethnicity, reason for methadone use, and results of urine toxicology screen. Overall, 85% of patients were using methadone for opiate addiction while 15% were using methadone for chronic pain. Birth weight, gestational age at delivery, the cesarean section rate, rate of preterm deliveries, 5-minute Apgar score of <7, and meconium-stained amniotic fluid were all no different between the 3 groups. For the entire group, the mean methadone dose at delivery was 97 mg. For the 70-mg group, it was 41 mg; for the 71-to 139-mg group, it was 107 mg; and for the 140-mg group, it was 159 mg. In the low-dose methadone group, 65% of infants were treated for NAS compared to 73% in the intermediate group and 100% in the high-dose group. The rate of treatment between the low-dose group and the intermediate group was no different; however, there was an increased rate of treatment when comparing the high-dose group to the low-dose group. When evaluating the length of treatment for NAS, for every 5.5-mg increase in methadone use in the mother, there was 1 additional day of treatment for NAS for the neonate.
Conclusions:
There is a direct relationship between increasing dosage of maternal methadone use and subsequent duration of treatment of NAS.
Reviewer's Comments: One limitation of this study was the small sample size. Although, the main strength of this study was the fact that not only was the incidence of NAS determined, but also the duration of treatment was presented. However, it appears from this study that reducing methadone usage from any level would help in decreasing the duration of treatment for NAS. 
Risk of Mortality in Monoamniotic Twins Appears to Occur Throughout Pregnancy
Perinatal Outcome of Monoamniotic Twin Pregnancies.
Hack KE, Derks JB, et al: Obstet Gynecol; There is a significant rate of fetal mortality with monoamniotic twins and this continues to occur even after 32 weeks' gestation.
Objective: To evaluate perinatal mortality and neonatal morbidity in monoamniotic twin gestations according to specific gestational ages.
Design/Methods: This was a retrospective study done over a 10-year period. Information was gathered from 10 referral centers on monoamniotic twin gestations. All monoamniotic twins had regular sonographic assessment of fetal growth, amniotic fluid volume, and Doppler interrogation of the umbilical artery. Stillbirth was an intrauterine death occurring 20 weeks' gestation. Perinatal mortality included stillbirths and neonatal deaths that were 28 days from delivery. Congenital heart abnormalities were noted. Cranial sonography was also used in order to evaluate any cerebral injury. The primary outcome evaluated was perinatal mortality.
Results: There were 98 monoamniotic twin gestations evaluated. Six (6%) were found to have twin-twin transfusion syndrome. Six pregnancies resulted in the death of both fetuses prior to 20 weeks' gestation. In 2 of the 6, mortality was thought to be secondary to cord entanglement, and for the other 4, the cause of death was not known. There were a total of 22 intrauterine fetal demises; 8 pregnancies had both twins expire, while 6 only had 1 twin expire. Three of those pregnancies in which there was 1 single fetal death had a subsequent neonatal death of the second twin. In all cases, this was related to cerebral artery infarction. In the remaining 3 co-twins death survivors, there was no cerebral injury noted. There were 12 neonatal deaths, of which 10 were single deaths while the other 2 were twins from the same pregnancy. When you consider the time from 20 weeks' gestation through 28 days of life, the perinatal mortality rate was 19%. If those fetuses and infants with lethal anomalies were excluded, then the overall perinatal mortality rate was 17%. With respect to mode of delivery, 40% of infants were delivered vaginally, and half of those were either pre-viable or were an unrecognized monoamniotic twin gestation. With respect to perinatal outcome, 87 of 164 liveborn infants (53%) required admission to the NICU. The median length of NICU stay was 6 days. Seven infants were found to have congenital heart abnormalities for a rate of 4%. Neonatal cerebral injury was noted in 5%.
Conclusions:
Perinatal mortality in monoamniotic twins has decreased in the past several decades, although it continues to be high and appears to occur throughout pregnancy.
Reviewer's Comments: It is difficult to predict fetal deaths in monoamniotic twins and it is also apparent that these may occur throughout pregnancy. In this study, 4 deaths occurred after 32 weeks' gestation, accounting for 4% of pregnancies. There continues to be controversy regarding optimal management and timing of delivery. 
Sonographic Markers for Growth Restriction, Low PAPP-A Predict Poor Outcomes
Second-Trimester Fetal Growth as a Predictor of Poor Obstetric and Neonatal Outcome in Patients With Low First-Trimester Serum Pregnancy-Associated Plasma Protein-A and a Euploid Fetus.
Fox NS, Shalom D, Chasen ST: Ultrasound Obstet Gynecol; 33 (January): [34] [35] [36] [37] [38] Among patients with low first-trimester PAPP-A and a euploid fetus, fetal growth in the second trimester can predict poor obstetric and neonatal outcome.
Objective: To determine whether a second-trimester sonogram assessment of fetal growth could predict a poor perinatal outcome in a euploid pregnancy with a decreased level of PAPP-A.
Design/Methods: This was a retrospective study done over a 4.5-year period. Singleton euploid pregnancies without malformations with a PAPP-A level <5th percentile were evaluated. All patients had a first-trimester sonographic evaluation and an evaluation between 18 to 24 weeks' gestation. Three sonographic findings were used at the second-trimester sonogram to identify fetal growth restriction. These included an estimated fetal weight of <25th percentile, a sonographic estimated gestational age <7 days from the previously determined estimated gestational age, and a head circumference/abdominal circumference (HC/AC) ratio >90th percentile for a specific gestational age. Two groups of patients were evaluated; those that had a decreased PAPP-A level and at least 1 of the second-trimester sonographic findings for growth restriction. The second group consisted of those with decreased PAPP-A levels, but had no second-trimester sonographic findings for fetal growth restriction.
Results: There were 239 patients with a PAPP-A level <5th percentile. Twenty-five of these (10.5%) had at least 1 sonographic marker at the second-trimester ultrasound for fetal growth restriction. Three had the isolated 7-day discrepancy between ultrasound gestational age and established gestational age; 8 were found to have only HC/AC asymmetry; and 2 were found to have only an estimated fetal weight <25th percentile. The other 12 had a combination of sonographic markers. When comparing those patients with low serum PAPP-A and normal growth parameters to those with low PAPP-A levels and evidence of fetal growth restriction, those with abnormal second-trimester sonogram findings had an increased rate of preterm delivery, gestational hypertension, preeclampsia, small for gestational age (SGA), low birth weight, low 1-minute Apgar scores, increased admission to the NICU, and fetal and/or neonatal death.
Conclusions:
In patients whose pregnancies are complicated by decreased first-trimester levels of PAPP-A and a euploid fetus, fetal growth assessment in the second trimester can assist in predicting poor perinatal and neonatal outcomes.
Reviewer's Comments:
With the increased use of first-trimester screening, it is important to be aware of low PAPP-A levels, especially in a euploid fetus. In this fetus, particular attention should be paid toward sonographic markers for growth restriction in the second trimester. Of patients that had a low PAPP-A level as well as second-trimester markers for fetal growth restriction, approximately 39% of fetuses were considered SGA and 21.7% were delivered with a birth weight <5th percentile. This was accompanied also by an increased risk of developing preeclampsia. There is a very high success of diagnosing gastroschisis prenatally. The survival rate of those infants born with gastroschisis is >90%.
Objective: To determine the prevalence of gastroschisis and associated anomalies, the ability to prenatally diagnose the condition, and the subsequent survival of infants with gastroschisis.
Design/Methods: This was a retrospective study done over a 10-year period. During this time, a perinatal database was used to identify pregnancies complicated by gastroschisis. The outcomes evaluated included prevalence of gastroschisis, the ability to prenatally diagnose gastroschisis, as well as maternal age-specific prevalence and subsequent survival. Total prevalence was the number of pregnancies affected by gastroschisis that resulted either in pregnancy termination, stillbirth, or live birth per 10,000 births. A live birth prevalence was the number of pregnancies with gastroschisis that subsequently had a live birth per 10,000 live births. Outcomes were also stratified by year of delivery.
Results: During a 10-year span, 143 cases of gastroschisis were identified. In total, 133 (93%) were isolated, while 10 had other anomalies. Five of 10 with gastroschisis with other anomalies had >1 associated abnormality. One case of gastroschisis had Klinefelter's syndrome and all the others had normal karyotypes. Overall, the total prevalence of gastroschisis was 4.28/10,000 births. In 1997, the total prevalence was 3.02 compared to 5.21 in 2006. Although an increase, this was not statistically significant. Live birth prevalence overall was 4.21/10,000 births with a live birth prevalence in 1997 of 3.04 compared to 4.62 in 2006; again, although increased, not statistically significant. In those cases of isolated gastroschisis, the mean maternal age at time of delivery was 21.1 years. Age-specific live birth prevalence rate was 18.6 if the maternal age was <20 years, 6.55 if the maternal age was between 20 and 24 years, 1.87 if between 25 and 29 years, and 0.66 if between 30 and 34 years. For non-isolated cases of gastroschisis, the mean maternal age was 22.4 years. With respect to survival, of the 133 cases of isolated gastroschisis, 2 ended in stillbirths, 1 was a pregnancy termination, but 130 (97.7%) resulted in live births. Of the 10 cases of non-isolated gastroschisis, 2 had pregnancy terminations and there were 8 livebirths. With respect to antenatal diagnosis of gastroschisis, prenatal diagnosis was made in 96.5% of cases.
Conclusions: There appears to be a trend toward an increase in gastroschisis, especially in young patients. There is a very high success of diagnosing gastroschisis prenatally. The survival rate of those infants born with gastroschisis is >90%.
It is interesting that the prevalence of gastroschisis appears to be highest in women aged <20 years. The reason for this is unclear. The prenatal detection rate for gastroschisis is also very high as is the survival rate. This information should be useful in counseling patients who are diagnosed with an infant with gastroschisis.
Reviewer's Comments: Although this was a prospective cohort study, it was really historical in nature looking back at an infertility population in whom some subsequently developed breast cancer. The authors find no overall relationship between gonadotropin or clomiphene citrate therapy on the risk of breast cancer, with the exception that women with a non-ovulatory disorder treated with high doses of clomiphene citrate statistically had a significantly increased risk of developing breast cancer. Interesting. Whole-body hyperthermia and carboplatin is associated with significant cardiac and hematologic toxicity.
Whole-Body Hyperthermia + Chemo Not Ready for Prime Time
Whole-Body Hyperthermia (WBH) in Combination With Carboplatin in Patients With
Objective: To investigate toxicity and efficacy of whole-body hyperthermia in combination with carboplatin. Participants/Methods: 47 patients with epithelial ovarian cancer were enrolled in the study. They had previously undergone at least 1 palliative treatment of chemotherapy. Of these 47 patients, 24 were classified as platinum refractory or resistant, and 16 as platinum sensitive. Patients received 6 cycles of carboplatin after a target temperature of 41.8C was reached and administered over 20 minutes.
Results: Significant severe hematologic toxicity was experienced by more than half the total, and cardiac complications occurred in nearly half. Median overall survival and progression-free survival were 61.5 and 29.0 weeks, respectively.
Conclusions:
Whole-body hyperthermia in combination with carboplatin is an active salvage treatment option with good response rates in patients with advanced ovarian cancer, yet the significant hematologic and cardiac toxicity renders this regimen inappropriate for palliative therapy. There is no conclusive evidence based on these and other data that whole-body hyperthermia has any advantage beyond chemotherapy alone.
Reviewer's Comments:
This was a phase II study (ie, not randomized) that looked at whole-body hyperthermia in conjunction with carboplatin therapy in patients with recurrent ovarian cancer. The toxicity of this combination is high and particularly, in patients with platinum refractory or resistant disease, it is a therapy with too many complications to be appropriate as a palliative regimen. 
AMH Assay Is Accurate Measure of Ovarian Reserve
Clinical Uses of Anti-Mllerian Hormone Assays: Pitfalls and Promises. Streuli I, Fraisse T, et al: Fertil Steril; Anti-Mllerian hormone assay is a valid measure of ovarian reserve at any time during the menstrual cycle.
Objective: To determine if anti-Mllerian hormone (AMH) levels fluctuate in relation to menstrual cycle phase or from differences between various immunoassays available.
Design/Methods: Prospective trial conducted at university hospitals, including 168 blood samples obtained from 3 different populations. Samples came from 95 women and AMH was measured using a Diagnostic Systems Laboratory kit, and the Beckman Coulter Immunotech kit. Additionally, serial samples were performed at set intervals from the luteinizing hormone (LH) surge in a population of 10 volunteers.
Results: There was a linear relationship between the 2 methods tested with high correlation. When individual AMH measures were longitudinally analyzed in relation to LH surge, a slight but significant decrease was observed post-ovulation.
Conclusions:
Fluctuations in levels of AMH rather than kit differences or inaccuracies are related to small changes in levels following ovulation, but it is not clinically relevant, making AMH measurements a valid method of assessing ovarian reserve.
Reviewer's Comments:
The objective of this study was very narrow really: to compare 2 immunoassay kits for accuracy and interchangeability. The main message, however, from a clinical standpoint is that AMH levels are stable under various influences such as hormonal contraception, menstrual cycle, and pregnancy. Measurements can be made any time to evaluate ovarian reserve. As this article points out, fluctuations after ovulation are slight but are smaller than inter-cycle variability and, thus, AMH remains a valid measure of ovarian reserve. Although endometrial polyps are common, occurring in approximately 8% of the population, it is rare that an endometrial polyp is the originating source of endometrial cancer.
Objective: To determine factors contributing to the pathogenesis of endometrial polyps. Design: Case-control study. Participants: 140 women with endometrial polyps and 367 controls without endometrial polyps. Methods: For a 14-month period (September 1, 2004 , through November 30, 2005 , women aged 36 to 74 years were recruited to participate in a population-based study of endometrial polyps. Women who were suspected of having an endometrial polyp on saline infusion sonohysterography underwent operative hysteroscopy, and presence of polyps was confirmed by histopathologic examination. Controls (n=367) were identified who did not have intrauterine disease. All participants in the study answered an 85-item questionnaire, which was specifically developed for the study that included possible associations with formation of polyps. Factors that were considered were age, menopausal status, body mass index, parity, gravidity, miscarriage, age at menopause, intermenstrual bleeding, menorrhagia, postmenopausal bleeding, diabetes, hypertension, thyroid disease, presence of cervical polyps, intestinal polyps, nose polyps, and polyps of the urinary bladder. In addition, investigators collected information about oral contraceptive use and hormone therapy use.
Results: There was no statistically significant difference in the 2 groups in parity, gravidity, number of miscarriages, or having ever experienced a miscarriage. In addition, there were no differences between cases and controls in smoking, alcohol consumption, education, and work. There were significantly more women who were obese in the endometrial polyp group than in the control group. In addition, hypertension, current use of hormone therapy, and ever use of hormone therapy were statistically more frequent in the postmenopausal endometrial polyp group than in controls. A total of 137 women were diagnosed with benign endometrial polyps, 3 had a polyp with premalignant disease, and another 3 women had a benign polyp with premalignant or malignant disease in the adjacent endometrium. One case had a polypoid lesion growing endometrial carcinoma.
Conclusions:
There is an association between endometrial polyps and use of hormone therapy and being overweight. Use of oral contraceptives appears to have a protective effect against endometrial polyps.
Reviewer's Comments: Exogenous hormone therapy and overweight are both conditions that may lead to chronic unopposed estrogen. Oral contraceptives have a predictable counter effect on endometrial proliferation and polyp formation. Any low-trauma fracture can be associated with significant increased mortality risks, since bone fragility is likely a reflection of underlying poor health.
Objective: To determine the association of fracture risks and long-term mortality in men and women. Design: Prospective cohort study. Participants: 452 women and 162 men with low-trauma osteoporotic fractures. Methods: As part of the Dubbo Osteoporotic Epidemiologic Study, men and women aged 60 years were followed longitudinally beginning in 1989. This cohort was assessed for physical activity, dietary calcium intake, cigarette smoking, alcohol consumption, number of falls in the last year, comorbid illnesses, and medications. Patients were followed with bone density measurements, quadriceps strength, and sway measurements. Interviews and measurements were conducted at 2-year intervals by a nurse coordinator for the study. Following a low-trauma fracture event, median time for follow-up was 13.1 years for women and 9.5 years for men. For purposes of this study, high-trauma fracture or fractures of the head, fingers, and toes were not analyzed. Vertebral fractures were identified by x-ray. Major fractures were considered to be fractures of the pelvis, distal femur, proximal tibia, 3 simultaneous ribs, and proximal humerus. Minor fractures included all remaining osteoporotic fractures. Mortality status was verified by death certificate.
Results: There were 952 fractures in women, and 343 in men from April 1989 through May 2007. This was equivalent to a fracture incidence of 32 per 1000 person-years. There was an increased mortality for all ages associated with all fractures except for minor fractures, in which there was increased mortality for only those persons aged 75 years. The increased risk for mortality persisted for up to 10 years for hip fractures, and up to 5 years for all fractures. Depending on the fracture type, the increased absolute mortality risks for women ranged from 1.3 to 13.2 per 100 person-years; and for men, from 2.7 to 22.3 per 100 person-years. Increased mortality hazard ratio for a subsequent fracture was 1.91 for women and 2.99 for men. Increasing age, quadriceps weakness, and subsequent fractures were predictors of mortality after any fragility fracture for both men and women. The patient's comorbidities were not predictors of mortality after a fragility fracture. Decrease in physical activity for men and low bone mineral density, having smoked, and sway were predictors for women.
Conclusions: Low-trauma fractures are associated with increased mortality risks at 5 to 10 years post-fracture for both men and women. An additional 5 years of increased mortality risk is associated with a subsequent fracture.
Reviewer's Comments:
The fragility of bones is reflective of poor underlying health. Although specific comorbidities are not related to low-trauma fractures, factors such as age, muscle weakness, poor vision, and low bone mineral density are all contributors. Of these, 2498 were reported to be MRSA and 1590 were reported as methicillin-susceptible S aureus. Between 1997 and 2001, there were increases in MRSA in surgical, non-teaching affiliated medical-surgical and cardiothoracic and coronary ICUs. There were no significant changes in the incidence of MRSA in medical units, teaching affiliated medical-surgical units, and pediatric units during this same study period. During the period from 2001 through 2007, there was a decrease in blood stream infections in all types of ICU units, except for pediatric units. They found that although the proportion of Staph aureus central line associated blood stream infections due to MRSA increased 25.8% of this study period, there was an overall decrease incidence of MRSA decreased by 49.6% during the same study period.
Conclusions:
In recent years, in most ICUs, there has been a decreased incidence of MRSA central line infection. Reviewer's Comments: MRSA is a nosocomial infection that has continually plagued health care settings.
Central line cultures from ICUs provide an objective way of determining the incidence of MRSA that may theoretically parallel the incidence in other areas of the hospital. This is important information for gynecologic surgeons. Uterine artery embolization is a successful technique in managing postpartum hemorrhage while allowing for conservation of the uterus.
Objective: To report the authors' experience using uterine artery embolization for treatment of intractable postpartum hemorrhage.
Design:
Retrospective study done over a 3.5-year period. Participants/Methods: During the study, there were 8779 deliveries, with 419 patients having postpartum hemorrhage, for a rate of 4.8%. All patients were managed initially with uterotonic agents, uterine massage, prostaglandin analogues, uterine packing, and B-lynch suturing. If there was failure of these techniques, then uterine artery embolization was undertaken. The embolization procedure included placement of an absorbable gelatin sponge in the anterior division of internal iliac artery. Success was verified by post-embolization angiogram.
Results: There were 419 patients with postpartum hemorrhage; 11 required uterine artery embolization, for a rate of 2.6%. Of these 11 patients, embolization was successful in 9 without complications. There were 2 cases with significant complications. In the first case, after initial embolization, there was persistent bleeding requiring a second embolization. There was persistent bleeding thought secondary to the blood supply of the ovarian arteries. Because of this, angiographic exploration of this area was begun, but subsequently abandoned and a hysterectomy performed. This patient also had a resultant neuropathy of the sciatic nerve requiring rehabilitation. One month after embolization, the patient was found to have a vesicovaginal fistula requiring repair. In the second patient, again, there was an initial embolization of the internal iliac arteries, but again, although the bleeding was less, it did not completely subside. Six hours later, a second embolization was done and, at that time, the right ovarian artery was also embolized. Post-embolization angiography showed occlusion of both internal iliac arteries as well as the right ovarian artery. However, after the second embolization during the confirmatory angiogram, the gelatin sponge material used for embolization was dislodged and migrated into the external iliac causing occlusion of the anterior and posterior tibial arteries as well as the peroneal artery and the small femoral artery branches. It was necessary to perform an embolectomy and fasciotomy. A second embolectomy was performed to establish appropriate blood flow. The patient, however, did develop complications, including necrosis of several muscles requiring removal of necrotic tissue.
Conclusions:
Uterine artery embolization is an alternative technique in the management of postpartum hemorrhage allowing for conservation of the uterus. Complications of embolization, however, should be considered.
Reviewer's Comments: Uterine artery embolization is an alternative procedure for management of postpartum hemorrhage. To use this technique, it should be performed quickly without delay. There are many minor complications reported with use of uterine artery embolization; however, as demonstrated in this study, there can be other more significant complications. Conversely, an emergency postpartum hysterectomy is not without complications. After embolization of the uterine artery, it is important to be able to recognize that possible complications may present as muscle pain, neurologic injury, and bladder dysfunction. Other signs that are concerning would be growing hematomas, infection, post-embolization ischemia, and infarction.
